The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

Detalhes bibliográficos
Autor(a) principal: Fernandes, G
Data de Publicação: 2021
Outros Autores: Martins, N, Machado, JC, Costa, JL, Hespanhol, V
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/155604
Resumo: Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.
id RCAP_8c2152bad8140d0632a68bc11fa0db17
oai_identifier_str oai:repositorio-aberto.up.pt:10216/155604
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) managementAdenocarcinomaCirculating cell-free tumour DNALiquid biopsyLung cancerNext Generation SequencingTumour genotypingLiquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.BMC20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/155604eng1475-286710.1186/s12935-021-02382-0Fernandes, GMartins, NMachado, JCCosta, JLHespanhol, Vinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-16T06:03:38Zoai:repositorio-aberto.up.pt:10216/155604Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:54:34.518241Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
title The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
spellingShingle The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
Fernandes, G
Adenocarcinoma
Circulating cell-free tumour DNA
Liquid biopsy
Lung cancer
Next Generation Sequencing
Tumour genotyping
title_short The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
title_full The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
title_fullStr The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
title_full_unstemmed The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
title_sort The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
author Fernandes, G
author_facet Fernandes, G
Martins, N
Machado, JC
Costa, JL
Hespanhol, V
author_role author
author2 Martins, N
Machado, JC
Costa, JL
Hespanhol, V
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Fernandes, G
Martins, N
Machado, JC
Costa, JL
Hespanhol, V
dc.subject.por.fl_str_mv Adenocarcinoma
Circulating cell-free tumour DNA
Liquid biopsy
Lung cancer
Next Generation Sequencing
Tumour genotyping
topic Adenocarcinoma
Circulating cell-free tumour DNA
Liquid biopsy
Lung cancer
Next Generation Sequencing
Tumour genotyping
description Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/155604
url https://hdl.handle.net/10216/155604
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1475-2867
10.1186/s12935-021-02382-0
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136433677533184

Registros relacionados